Organisation und Erkenntnisse einer Pilotstudie zur allergologischen Abklärung einer COVID-19-Impfstoffallergie in der Weihnachtswoche 2021

Bent, Rebekka; Faihs, Valentina; Darsow, Ulf; Biedermann, Tilo; Brockow, Knut

doi:10.5414/alx02378

Cited by 2 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients who had developed symptoms after previous vaccination (VSBT) were mostly female as has been described 12,26 and were only slightly scared (0-3 points) before the first COVID-19 vaccination (77.4%). Reported allergic symptoms after vaccination were mostly subjective and may be-at least partially-explained through vasovagal or nonimmune-mediated anxiety or stress mechanisms.…”

Section: Discussionmentioning

confidence: 99%

“…In a previous study, we had optimized clinical processes of COVID-19 vaccine allergy testing to increase the numbers of tested patients during the COVID-19 pandemic and showed how optimizing intraclinical processes leads to a substantially higher number of patients that can be allergy tested and vaccinated. 12 Differently than in this study, patients asking for allergy testing without medical test indication were kept to a minimum and were exceptional.…”

mentioning

confidence: 89%

“…The incidences of anaphylaxis to COVID‐19 vaccines is low at 2.5/million (Spikevax®) and 4.7/million (Comirnaty®) 9–11 . Nonetheless, there is public uncertainty and doubt about the safety of the newly developed mRNA vaccines 12–15 . People continue to reject COVID‐19 vaccination because they fear side effects such as allergies/anaphylaxis 16,17 .…”

Section: Introductionmentioning

confidence: 99%

“…9-11 Nonetheless, there is public uncertainty and doubt about the safety of the newly developed mRNA vaccines. [12][13][14][15] People continue to reject COVID-19 vaccination because they fear side effects such as allergies/anaphylaxis. 16,17 Without prior allergy testing, parts of the population are unwilling to get vaccinated.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Increasing the COVID‐19 immunization rate through allergy testing

Bent

Weinbrenner

Faihs

et al. 2023

Acad Dermatol Venereol

Self Cite

View full text Add to dashboard Cite

Background Vaccination of the population is required to combat the COVID‐19 pandemic. Allergy testing could reduce anxiety towards COVID‐19 vaccination and thereby may increase vaccination rate, however, its effectiveness remains unclear. Methods One hundred and thirty prospective real‐life patients in need of but not daring to get vaccinated asked for allergy workup for COVID‐19 vaccine hypersensitivity in 2021/2022. Characterization of patients, identification of anxieties, decrease of patient's anxiety levels, overall vaccination rate and adverse reactions after vaccination were assessed. Results Tested patients were characterized by being female (91.5%) and having a high rate of previous allergies (e.g. to food 55.4%, drugs 54.6%, or previous vaccinations 50%) and dermatological disease (29.2%) but not always had medical contraindications for COVID‐19 vaccination. Sixty one patients (49.6%) were highly concerned (4‐6, Likert scale 0‐6) about vaccination and 47 (37.6%) expressed resolving thoughts about vaccinaion anaphylaxis (3‐6, Likert scale 0‐6). However only 35 patients (28.5%) were scared of getting COVID‐19 within 2 months (4–6, Likert scale 0–6) and only 11 (9%) patients had high expectations of getting COVID‐19 (4–6, Likert scale 0–6). Allergy testing significantly (p < 0.01 to p < 0.05 respectively) reduced the median anxiety of allergic symptoms following vaccination: dyspnoea (4.2–3.1), to faint (3.7–2.7), long‐term consequences (3.6–2.2), pruritus (3.4–2.6), skin rash (3.3–2.6) and death (3.2–2.6). After allergy testing, most patients (108/122, 88.5%) let themselves be vaccinated within 60 days. Revaccinated patients with previous symptoms experienced a reduction of symptoms (p < 0.05) upon revaccination. Conclusions Patients not daring to get vaccinated have more anxiety towards vaccination than to acquire COVID‐19. For those, allergy testing excludes vaccine allergy, and is a tool to increase vaccination willingness and thereby helps to combat vaccination hesitancy.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 89%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Increasing the COVID‐19 immunization rate through allergy testing

Bent

Weinbrenner

Faihs

et al. 2023

Acad Dermatol Venereol

Self Cite

View full text Add to dashboard Cite

show abstract

“…It was initially assumed that the majority of anaphylaxis would be triggered by PEG. We organized a SARS-CoV-2 vaccine testing week for patients with justified or unjustified fear of vaccination; to exclude possible PEG allergy, the history was taken and skin prick tests done at 30-minute intervals [ 44 ]. We were able to show that the increasing number of appointment requests in an allergy department could be handled efficiently and promptly in this way, that fears were relieved, and most patients subsequently had themselves vaccinated without developing a reaction.…”

Section: Allergy Workup Before Sars-cov-2 Vaccinationmentioning

confidence: 99%

SARS-CoV-2 and allergy – what have we learned after two and a half years?

Brockow¹,

Wang²,

Mathes³

et al. 2023

ALS

View full text Add to dashboard Cite

Background: Coronavirus disease-2019 (COVID-19) has significantly hampered the regular workflow for allergists and allergy departments. Materials and methods: The purpose of this review is to highlight our own experiences on SARS-CoV-2 and allergy as well as to discuss findings from the literature. Results: Vaccination against SARS-CoV-2 is needed for protection against severe infection. Skin reactions may arise with SARS-CoV-2 infections. Short-term general immune reactions and skin reactions are also possible upon SARS-CoV-2 vaccination; however, they recur in only a proportion of patients during follow-up vaccinations. Initial reports of anaphylaxis after vaccination fueled public fear. On the other hand, more recent epidemiologic data do not show a substantially increased anaphylaxis risk compared with other vaccines. Fear-related reactions may be essential for many “anaphylaxis” reports. In Germany, the flow chart developed by Paul-Ehrlich-Institut (PEI) and Robert-Koch-Institut (RKI) together with the allergological societies helps to care for patients with suspected “allergy history” safely and effectively. Through this, patients with increased risk of anaphylaxis to SARS-CoV-2 vaccines and their ingredients (e.g., polyethylene glycol (PEG), polysorbate 80) are identified. However, since only small amounts of these excipients are contained in mRNA vaccines, even some PEG-allergic patients can tolerate the vaccination. In Germany, an allergy test-guided procedure is recommended for high-risk patients, including an allergy history, prick tests, intradermal and basophil activation tests, and, if necessary, provocation tests. This also appears effective for anxiety reduction in patients with vaccination skepticism. To date, all of our patients have been able to be vaccinated with SARS-CoV-2 vaccines without the occurrence of significant reactions. Conclusion: Many initial concerns about unexpected side effects of SARS-CoV-2 vaccination have not been confirmed. The flowchart and, in the case of suspicion of hypersensitivity, an allergy test-guided risk assessment helps to reduce patients’ fear of vaccination and enables safe vaccination.

show abstract

Organisation und Erkenntnisse einer Pilotstudie zur allergologischen Abklärung einer COVID-19-Impfstoffallergie in der Weihnachtswoche 2021

Cited by 2 publications

References 0 publications

Increasing the COVID‐19 immunization rate through allergy testing

Increasing the COVID‐19 immunization rate through allergy testing

SARS-CoV-2 and allergy – what have we learned after two and a half years?

Contact Info

Product

Resources

About